Angiotensin II-pretreated Hucmscs Attenuate Inflammation and Reverse Pulmonary Fibrosis in SD Rat Lung

Wei Wang,Aishi Song,Weiyue Deng,Yuying Zhang,Omar Mukama,Jean de Dieu Habimana,Wei Xie,Peng Zhou,Amy L. Li,Jiaxing Li,Sihao Deng,Bin Ni,Kexin Peng,Shusheng Zhang,Xiaoxin Yan,Jufang Huang,Zhiyuan Li

DOI: https://doi.org/10.21203/rs.3.rs-1763097/v1

2022-01-01

Abstract:Abstract Background: Pulmonary fibrosis (PF) is an irreversible disease with a poor prognosis and a serious impact on patients' health. PF is also associated with COVID-19, especially in immunocompromised people. Herein, efforts have been made to treat PF using pretreatment of human umbilical cord mesenchymal stem cells (hucMSCs) with angiotensin II (Ang II) as a novel therapeutic method. Methods: PF model of Sprague Dawley (SD) rats were established by tracheal injection of bleomycin (BLM) (5U/Kg). On day 15 after modeling, PBS, hucMSCs or hucMSCs-Ang II were injected into tail vein. On the 23rd day after modeling, samples were taken and corresponding indexes were tested.Results: Our results first showed that Ang II pretreatment induced more hucMSCs to reach the injured lung and alleviated pulmonary fibrosis. Transplantation of hucMSCs-Ang II reduced inflammatory infiltration, increased IL-10 expression and enhanced macrophage matrix-metallopeptidase-9 (MMP-9) expression for collagen degradation. Moreover, the Ang II-treated hucMSCs decreased hydroxyproline (HYP) and alpha-smooth muscle actin (α-SMA) expression in SD rats and promoted collagen and collagen fiber degradation.Conclusions: Ang II pretreatment enhanced the homing ability of hucMSCs, and hucMSCs-Ang II transplantation reversed PF by inhibiting inflammation and promoting collagen and collagen fiber degradation, promising its clinical application in the treatment of post-inflammatory PF caused by various disorders, including COVID-19 and related pneumonia.